A Randomized, Placebo-Controlled Trial of Granulocyte Colony-stimulating Factor Administration to Newborn Infants With Neutropenia and Clinical Signs of Early-onset Sepsis

Schibler, Kurt; Osborne, Karen A.; Leung, Ling; Le, Trong V.; Baker, Shawna; Thompson, Dixie D

doi:10.1542/peds.102.1.6

Cited by 114 publications

(65 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relative neutropenia was the biggest risk factor causing death figure was smaller than that studied by Funke et al, Gender, prematurity, birth weight, maternal infection or referrals were not predictors of death of bacterial neonatal sepsis. These results were similar to a study by Schiber et al 8 .…”

Section: Resultssupporting

confidence: 93%

Association between neutropenia and death rate of bacterial neonatal sepsis

Rochmah¹,

Haksari²,

Mulatsih³

2016

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 93%

Association between neutropenia and death rate of bacterial neonatal sepsis

Rochmah¹,

Haksari²,

Mulatsih³

2016

View full text Add to dashboard Cite

show abstract

“…Intravenous immunoglobulin (IVIG) therapy in this setting did not demonstrate any improvement of patient outcome versus antimicrobial therapy alone (256). Recombinant granulocyte colony-stimulating factor (rG-CSF) administered to neonates with neutropenia and sepsis showed no differences in severity of illness, morbidity, or mortality compared to placebo (257). So far, no adjunctive therapy to antibiotics has been proven beneficial in the management of neonatal sepsis (258).…”

Section: Alternative/adjunctive Therapymentioning

confidence: 95%

Early-Onset Neonatal Sepsis

et al. 2014

View full text Add to dashboard Cite

SUMMARY Early-onset sepsis remains a common and serious problem for neonates, especially preterm infants. Group B streptococcus (GBS) is the most common etiologic agent, while Escherichia coli is the most common cause of mortality. Current efforts toward maternal intrapartum antimicrobial prophylaxis have significantly reduced the rates of GBS disease but have been associated with increased rates of Gram-negative infections, especially among very-low-birth-weight infants. The diagnosis of neonatal sepsis is based on a combination of clinical presentation; the use of nonspecific markers, including C-reactive protein and procalcitonin (where available); blood cultures; and the use of molecular methods, including PCR. Cytokines, including interleukin 6 (IL-6), interleukin 8 (IL-8), gamma interferon (IFN-γ), and tumor necrosis factor alpha (TNF-α), and cell surface antigens, including soluble intercellular adhesion molecule (sICAM) and CD64, are also being increasingly examined for use as nonspecific screening measures for neonatal sepsis. Viruses, in particular enteroviruses, parechoviruses, and herpes simplex virus (HSV), should be considered in the differential diagnosis. Empirical treatment should be based on local patterns of antimicrobial resistance but typically consists of the use of ampicillin and gentamicin, or ampicillin and cefotaxime if meningitis is suspected, until the etiologic agent has been identified. Current research is focused primarily on development of vaccines against GBS.

show abstract

“…Further, a significant reduction (61%) in the incidence of nosocomial infections in VLBW was reported (34). Exceptionally, Schibler et al (60) reported no effect of G-CSF administration on neutrophil counts and maturation and in the outcome of preterm and full-term septic babies. In contrast to others, these investigators pooled together preterm with full-term neonates in the analysis of the data.…”

Section: Discussionmentioning

confidence: 99%